文章：

肿瘤特异性CD160检测微小残留病与慢性淋巴细胞白血病无事件生存相关

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia

原文发布日期：2015-01-23

DOI: 10.1038/bcj.2014.92

类型: Original Article

开放获取: 是

英文摘要：

In chronic lymphocytic leukemia (CLL), the detection of minimal residual disease (MRD) correlates with outcome in the trial setting. However, MRD assessment does not guide routine clinical management and its assessment remains complex. We incorporated detection of the B cell, tumor-specific antigen CD160 to develop a single-tube, flow cytometry assay (CD160FCA) for CLL MRD to a threshold of 10−4 to 10−5. One hundred and eighty-seven patients treated for CLL were enrolled. Utilizing the CD160FCA methodology, there was a high level of comparison between blood and bone marrow (R=0.87, P<0.001). In a validation cohort, CD160FCA and the international standardised approach of the European Research Initiative on CLL group demonstrated high concordance (R=0.91, P<0.01). Patients in complete remission (CR) and CD160FCA negative had longer event-free survival (EFS) (63 vs 16 months, P<0.01) and prolonged time to next treatment (60 vs 15 months, P<0.001) vs MRD positive patients; with a median time to MRD positivity of 36 months. In multivariate analysis, CD160FCA MRD detection was independently predictive of EFS in patients in CR and even predicted EFS in the good-risk cytogenetic subgroup. CD160FCA offers a simple assay for MRD detection in CLL and gives prognostic information across different CLL risk groups.

摘要翻译： 

在慢性淋巴细胞白血病（CLL）中，微小残留病（MRD）的检测在临床试验环境中与预后相关。然而，MRD评估目前并不指导常规临床管理，且其检测过程仍较为复杂。我们通过检测B细胞特异性肿瘤抗原CD160，开发了灵敏度达10⁻⁴至10⁻⁵水平的单管流式细胞术检测方法（CD160FCA）用于CLL的MRD检测。本研究纳入187例接受治疗的CLL患者。采用CD160FCA方法学分析显示，外周血与骨髓样本检测结果具有高度一致性（R=0.87，P<0.001）。在验证队列中，CD160FCA与欧洲CLL研究倡议组织制定的国际标准化方案呈现高度吻合（R=0.91，P<0.01）。与MRD阳性患者相比，达到完全缓解（CR）且CD160FCA阴性的患者具有更长的无事件生存期（63个月 vs 16个月，P<0.01）和更长的至下次治疗时间（60个月 vs 15个月，P<0.001），其中位MRD转阳时间为36个月。多变量分析显示，在CR患者中，CD160FCA的MRD检测是EFS的独立预测因子，即使在良好风险细胞遗传学亚组中也能预测EFS。CD160FCA为CLL的MRD检测提供了简便方法，并能跨不同CLL风险组别提供预后信息。

原文链接：

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia